MET-PREVENT: metformin to improve physical performance in older people with sarcopenia and physical prefrailty/frailty - protocol for a double-blind, randomised controlled proof-of-concept trial.

ABSTRACT:

Introduction

Skeletal muscle dysfunction is central to both sarcopenia and physical frailty, which are associated with a wide range of adverse outcomes including falls and fractures, longer hospital stays, dependency and the need for care. Resistance training may prevent and treat sarcopenia and physical frailty, but not everyone can or wants to exercise. Finding alternatives is critical to alleviate the burden of adverse outcomes associated with sarcopenia and physical frailty. This trial will provide proof-of-concept evidence as to whether metformin can improve physical performance in older people with sarcopenia and physical prefrailty or frailty.

Methods and analysis

MET-PREVENT is a parallel group, double-blind, placebo-controlled proof-of-concept trial. Trial participa

SUBMITTER: Rennie KJ 

PROVIDER: S-EPMC9297211 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature